Medical Patent News

RSS

Silence Therapeutics receives two patents for RNA interference therapeutics

Silence Therapeutics plc announces the issuance of two new patents by the United States Patent and Trademark Office (USPTO) which are broadly directed to double-stranded short interfering RNA (siRNA) sequences against the validated cancer targets epidermal growth factor receptor related protein (EGFR-RP) and vascular endothelial growth factor receptor 1 (VEGFR1).

8 Sep 2010

K-State University receives patent for procedures to source stem cells from umbilical cord

Kansas State University has been a issued a patent for a plentiful and noncontroversial source of stem cells from a substance in the umbilical cord.

8 Sep 2010

DiaTech Oncology files patent for Drug Discovery to validate cancer treatment

DiaTech Oncology has announced the filing of a patent for Drug Discovery that will provide a new strategy and approach to validate drugs that may be more effective in treating cancer patients

8 Sep 2010

BioAlliance Pharma receives European patent for acyclovir Lauriad tablets for recurrent herpes labialis

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, today announced the grant of a European patent protecting its product acyclovir Lauriad.

8 Sep 2010

Estee Lauder subsidiary and OXIS resolve mitochondria patent dispute

OXIS INTERNATIONAL, INC. and THE ESTEE LAUDER COMPANIES INC. announce today that they have resolved a dispute between an Estee Lauder subsidiary, Applied Genetics Incorporated Dermatics, and Oxis over technology related to U.S. Patent No. 6,103,746 and U.S. Patent No. 6,479,533, entitled "Methods and Compositions for the Protection of Mitochondria."

7 Sep 2010

Precision receives stay for patent infringement litigation by Cellectis

Precision BioSciences, Inc., today announced that the United States District Court for the Eastern District of North Carolina has granted Precision's request to stay patent infringement litigation brought against Precision by Cellectis, SA.

7 Sep 2010

Lilly's Evista method patents upheld through March of 2014

Eli Lilly and Company today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company's method-of-use patents for Evista® (raloxifene HCl tablets) are valid. These patents provide protection for Evista in the U.S. through March of 2014.

2 Sep 2010

Amedica Corporation receives patent for knee implant prosthesis with monoblock ceramic tibial component

Amedica Corporation, a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today that it has been granted United States Patent No. 7,776,085 B2, covering an improved knee implant prosthesis that features a monoblock ceramic tibial component for articulation with natural or prosthetic (resurfaced) femoral surfaces.

2 Sep 2010

TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

TPP Global Development Ltd (TPP) announced an agreement with the University of Edinburgh to collaborate on the development of novel pre-clinical intellectual property originated within the University.

31 Aug 2010

Bend Research granted patent for making solid amorphous dispersions of drugs with SDD technology

Bend Research Inc., a leading independent drug-formulation development and manufacturing company, announced today that it has received a new U.S. patent covering a process for making spray-dried solid amorphous dispersions of drugs using pressure nozzles.

30 Aug 2010

KemPharm broadens protection for LAT prodrug technology platform for ADHD with second patent

KemPharm, Inc. announced today that it has received a Notice of Issuance from the United States Patent and Trademark Office (USPTO) for its patent application entitled "Non-Standard Amino Acid Conjugates of Amphetamine and Processes for Making and Using the Same", U.S. Patent No. 7,776,917 B2. This patent, combined with KemPharm's recently issued U.S. Patent No. 7,772,222, provides broad protection of the Company's Ligand Activated Therapy (LAT) prodrug technology platform and its application to the treatment of Attention Deficit – Hyperactivity Disorder.

27 Aug 2010

Shire receives European marketing approval for VPRIV therapy to treat type 1 Gaucher disease

Shire, the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV(R) (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease.

27 Aug 2010

EPO allows patent for CEM's proprietary microwave peptide synthesis process

CEM Corporation, a leading global provider of microwave laboratory instrumentation, is pleased to announce that its patent claims for the microwave peptide synthesis process have now been allowed in Europe by the European Patent Office.

27 Aug 2010

CreAgri receives patent for Hydroxytyrosol for skin damage by UV exposure

CreAgri, Inc. announced today that the company has received a Patent by the Australian Patent Office, Patent Number 2003249719, which covers the protective effects provided by Hydroxytyrosol against skin damage caused by UV exposure.

26 Aug 2010

AdvanSource receives patent for Antimicrobial Polyurethane Resins to eradicate MRSA

AdvanSource Biomaterials Corporation, a leading developer, manufacturer and seller of advanced polymer technologies and materials for a broad range of medical devices, today announced that it has received a "Notice of Allowance" from the U.S. Patent and Trademark Office in connection with its antimicrobial patent application filed in June 2007. U.S. Patent No. 7,772,296, which is entitled "Antimicrobial Polyurethane Resins and Products Made Therefrom," covers a drug-free, antimicrobial technology to eradicate Methicillin-resistant Staphylococcus aureus ("MRSA") clinical infections associated with medical devices.

26 Aug 2010

Biomoda's CyPath assay for lung cancer detection receives Canadian patent

Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.

26 Aug 2010

TRT receives patent rights for procedure of reattaching damaged soft tissue to bone

Tissue Regeneration Technologies, LLC (TRT), a Woodstock, Georgia medical technology company, recently received the rights to a new patent to bolster its SoftWave technology portfolio. The patent covers a method of reattaching damaged soft tissue to bone.

26 Aug 2010

Nabi receives US patent for treatment and prevention of nicotine addiction with NicVAX conjugate vaccines

Nabi Biopharmaceuticals announced the receipt of a patent for treating and preventing nicotine addiction with NicVAX® and related nicotine conjugate vaccines. The United States Patent and Trademark office issued U.S. Patent No. 7,776,620 entitled "Hapten-carrier conjugates for treating and preventing nicotine addiction" for the exclusive use of methods for treating and preventing nicotine addiction with NicVAX and related nicotine vaccines. This patent runs through December 2018.

26 Aug 2010

Advaxis' 'Prokaryotic peptides for enhancing antigen immunogenicity' European patent application allowed

Advaxis, Inc.,, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has been notified by the European Patent Office that patent application WO2001/072329, for the use of Prokaryotic PEST-Like Peptides for Enhancing Immunogenicity of Antigen has been allowed for issuance. This patent will be #1,303,299 when granted, and will be licensed exclusively to Advaxis by the University of Pennsylvania.

26 Aug 2010

Celera granted US patent on LPA gene variant's association with increased risk for myocardial infarction

Celera Corporation today announced that the United States Patent and Trademark Office has issued United States Patent 7,781,168 relating to methods of determining heart attack risk by detecting the Ile4399Met genetic polymorphism in the protease-like domain of LPA.

25 Aug 2010

Medical Patent News

Silence Therapeutics receives two patents for RNA interference therapeutics

K-State University receives patent for procedures to source stem cells from umbilical cord

DiaTech Oncology files patent for Drug Discovery to validate cancer treatment

BioAlliance Pharma receives European patent for acyclovir Lauriad tablets for recurrent herpes labialis

Estee Lauder subsidiary and OXIS resolve mitochondria patent dispute

Precision receives stay for patent infringement litigation by Cellectis

Lilly's Evista method patents upheld through March of 2014

Amedica Corporation receives patent for knee implant prosthesis with monoblock ceramic tibial component

TPP and University of Edinburgh collaborate on development of novel pre-clinical intellectual property

Bend Research granted patent for making solid amorphous dispersions of drugs with SDD technology

KemPharm broadens protection for LAT prodrug technology platform for ADHD with second patent

Shire receives European marketing approval for VPRIV therapy to treat type 1 Gaucher disease

EPO allows patent for CEM's proprietary microwave peptide synthesis process

CreAgri receives patent for Hydroxytyrosol for skin damage by UV exposure

AdvanSource receives patent for Antimicrobial Polyurethane Resins to eradicate MRSA

Biomoda's CyPath assay for lung cancer detection receives Canadian patent

TRT receives patent rights for procedure of reattaching damaged soft tissue to bone

Nabi receives US patent for treatment and prevention of nicotine addiction with NicVAX conjugate vaccines

Advaxis' 'Prokaryotic peptides for enhancing antigen immunogenicity' European patent application allowed

Celera granted US patent on LPA gene variant's association with increased risk for myocardial infarction

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News